Bridges Investment Management Inc. Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bridges Investment Management Inc. bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,069 shares of the medical equipment provider's stock, valued at approximately $487,000.

Several other institutional investors also recently bought and sold shares of LNTH. UMB Bank n.a. boosted its holdings in shares of Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after buying an additional 208 shares in the last quarter. Principal Securities Inc. bought a new position in Lantheus during the fourth quarter valued at approximately $28,000. Fidelis Capital Partners LLC purchased a new position in Lantheus during the 1st quarter valued at approximately $34,000. Finally, FinTrust Capital Advisors LLC increased its stake in Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock worth $41,000 after acquiring an additional 232 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Up 1.4 %

Shares of NASDAQ LNTH opened at $110.05 on Friday. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The firm has a 50-day simple moving average of $105.51 and a two-hundred day simple moving average of $84.24. The company has a market cap of $7.63 billion, a P/E ratio of 16.80 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. During the same quarter in the previous year, the firm earned $1.40 EPS. Lantheus's revenue was up 22.5% compared to the same quarter last year. Research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Insider Transactions at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares of the company's stock, valued at $2,047,402.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now directly owns 98,980 shares of the company's stock, valued at $9,540,682.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,852 shares of company stock worth $3,922,001. Insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LNTH. JMP Securities lowered their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research report on Thursday, August 1st. Leerink Partners lifted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price on the stock. B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Finally, Truist Financial dropped their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.